An Observational Study on The Correlation Between Time of Initiation of Avastin (Bevacizumab) Treatment And Progression-Free Survival in Patients With Colorectal Cancer (CRONOS 1)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01277120 |
Recruitment Status
:
Terminated
(Contract terminated with Site Management Organization)
First Posted
: January 14, 2011
Last Update Posted
: September 15, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Colorectal Cancer |
Study Type : | Observational |
Actual Enrollment : | 174 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | The Correlation Between the Moment of Bevacizumab theRapy initiatiOn and the Efficacy in patieNt With cOlorectal Cancer Treated With AvaStin Based First Line Regimens (CRONOS 1) |
Study Start Date : | April 2010 |
Actual Primary Completion Date : | April 2016 |
Actual Study Completion Date : | April 2016 |

Group/Cohort |
---|
Cohort |
- Correlation of the time from the start of chemotherapy to the start of Avastin treatment with progression-free survival [ Time Frame: 60 months ]
- Overall survival [ Time Frame: 60 months ]
- Safety: Incidence of adverse events [ Time Frame: 60 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Adult patients, >/= the 18 years of age
- Previously untreated metastatic colorectal cancer
- Scheduled to start 1st line chemotherapeutic treatment
- ECOG performance status 0-1
Exclusion Criteria:
- Any conditions included in contraindication list for Avastin
- Prior chemotherapy for metastatic colorectal cancer
- Adjuvant/neoadjuvant chemotherapy or radio-chemotherapy of non-metastatic colorectal cancer completed <6 months prior to treatment start

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01277120
Romania | |
Bucharest, Romania, 022328 |
Study Director: | Clinical Trials | Hoffmann-La Roche |
Responsible Party: | Hoffmann-La Roche |
ClinicalTrials.gov Identifier: | NCT01277120 History of Changes |
Other Study ID Numbers: |
ML25178 |
First Posted: | January 14, 2011 Key Record Dates |
Last Update Posted: | September 15, 2016 |
Last Verified: | September 2016 |
Additional relevant MeSH terms:
Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases |
Intestinal Diseases Rectal Diseases Bevacizumab Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Growth Inhibitors Antineoplastic Agents |